We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Two Rapid Tests for Diagnosis of the Novel Chinese Coronavirus

By LabMedica International staff writers
Posted on 13 Feb 2020
Two new rapid diagnostic tests are set to enable clinicians to detect individuals infected with the potentially pandemic “Chinese” coronavirus.

A novel coronavirus of zoonotic origin (2019-nCoV) has recently been identified in patients with acute respiratory disease. More...
This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city of China, but has subsequently been detected in other provinces of China as well as in several other countries.

Signs of infection are highly non-specific and these include respiratory symptoms, fever, cough, dyspnea, and viral pneumonia. Currently, experts estimate that only 5.1% of coronavirus cases in Wuhan have actually been diagnosed clinically. Therefore, diagnostic tests specific for this infection are urgently needed for confirming suspected cases, screening patients, and conducting virus surveillance.

In this regard, investigators at the University of Hong Kong (China) developed two rapid tests for detection of coronavirus. The two one-step quantitative real-time reverse-transcription PCR (RT-PCR) assays detect two different regions (ORF1b and N) of the viral genome. The primer and probe sets were designed to react with this novel coronavirus and closely related viruses, such as SARS coronavirus. These assays, which require only about an hour and a quarter to perform, were evaluated using a panel of positive and negative controls. In addition, respiratory specimens from two 2019-nCoV-infected patients were tested.

Using RNA extracted from cells infected by SARS coronavirus as a positive control, these assays were shown to have a dynamic range of at least seven orders of magnitude.. Using DNA plasmids as positive standards, the detection limits of the assays were found to be below 10 copies per reaction. All negative control samples were negative in the assays. Samples from two 2019-nCoV-infected patients were positive in the tests. The negative results for samples containing genetic material from other respiratory viruses demonstrated that the tests accurately differentiated coronavirus infection from other causes of pneumonia.

“Signs of [coronavirus] infection are highly non-specific and these include respiratory symptoms, fever, cough, [shortness of breath], and viral pneumonia,” said senior author Dr. Leo L.M. Poon, professor of public health at the University of Hong Kong. “Thus, diagnostic tests specific for this infection are urgently needed for confirming suspected cases, screening patients, and conducting virus surveillance. The established assays [in this study] can achieve a rapid detection of 2019-novel-coronavirus in human samples, thereby allowing early identification of patients.”

The new assays were described in the January 31, 2020, online edition of the journal Clinical Chemistry.

Related Links:
University of Hong Kong


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.